San Jose, Calif.-based Anpac Bio-Medical Science Co. Ltd., a company with operations in China and the U.S. focused on early cancer screening and detection, entered a sales contract in mid-August 2020 with Beijing Yuan Jian Health Management Co. Ltd. in China for the company’s newly launched immunology test, Anpac Defense Medical Examination (ADME). Beijing Yuan Jian Health Management has already been a client of Anpac for the past two years. The contract has a duration of 14 months and includes 20,000 paid ADME tests, with the expectation that the test is to be offered to end customers at multiple locations in China.
The government of Singapore and Cupertino, Calif.-based Apple Corp. reported their partnership on the health initiative Lumihealth, a personalized program to encourage healthy activity and behaviors using Apple Watch. The program was designed by Singapore’s Health Promotion Board in conjunction with Apple as part of the country’s Smart Nation initiative, a national effort to leverage technology to deliver benefits to its citizens and businesses. Created in collaboration with a team of physicians and public health experts, Lumihealth uses technology and behavioral insights to encourage Singaporeans to keep healthy and complete wellness challenges through their Apple Watch and iPhone. The Lumihealth app is available in the App Store for pre-order now, and the two-year program will be offered from late October 2020.
Waltham, Mass.-based Bostongene Corp., a reported a scientific collaboration with Brigham and Women’s Hospital. In this collaboration, Bostongene provides the analysis of whole transcriptome sequencing (RNA seq) data sets generated from tumor and blood samples from patients with recurrent glioblastoma treated with an oncolytic virus as part of a phase I clinical trial. As part of the effort, Bostongene correlation analysis aims to identify novel biomarkers of response to therapy.
Ramat Gan, Israel-based, Cardiacsense Ltd. has signed an exclusive distribution agreement valued at $7.5 million to distribute the company's medical wristwatches in the United Arab Emirates (UAE). This is the tenth distribution agreement that Cardiacsense has signed since March 2020, bringing the total value of the agreements signed to more than $70 million, the company said. The exclusive distribution agreement in the UAE is slated to run over a period of four years. The distributing company operates out of Dubai and engages in the distribution of medical equipment in the UAE.
Concept Medical Inc., of Tampa, Fla., reported the first patient enrolled in its randomized, double-blind, placebo-controlled, multicenter FUTURE SFA clinical trial. The study will evaluate the effectiveness of the company’s Magictouch PTA sirolimus drug-coated balloon vs. standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal arterial disease. The index patient was successfully enrolled in Singapore.
Atlanta-based Controlrad Inc. said it has closed a series C financing led by current investor Questa Capital. The size of the round was not disclosed.
Fujifilm Sonosite Inc., of Bothell, Wash., and the Chest Foundation, the charitable foundation of the American College of Chest Physicians, are partnering on a program to investigate the role of point-of-care ultrasound (POCUS) in the intensive care unit through the Chest Foundation Research Grant in Ultrasonography and COVID-19. Under the collaboration, Fujifilm Sonosite will contribute up to two grants of $30,000 to the Chest Foundation in support of the program and will donate its newly launched Sonosite Px ultrasound systems to the select research award sites.
Genetic Technologies Ltd., of Melbourne, Australia, said it has completed development of a prototype polygenic risk score and clinical risk model for its COVID-19 disease severity test, and has assessed the combined comprehensive risk model. Sourced cross validation data is expected in late September or early October. The company is in talks with a potential partner for pilot scale implementation and has completed a preliminary analysis of “Workforce Management by Polygenetic Testing.”
Global Plasma Solutions Inc., of Charlotte, N.C, has launched its needlepoint bipolar ionization to virtually eliminate static SARS-CoV-2.
San Diego-based Illumina Inc. said the Communicable Disease Genomics Network is collaborating with Australian public health laboratories to track COVID-19 using next-generation sequencing technology. The Australian government has provide a AU$3.3 million (US$2.4 million) Medical Research Future Fund grant through The University of New South Wales Sydney’s School of Medical Sciences. As part of the research effort, Illumina has contributed more than AU$2 million of its genomic sequencing systems and related consumables.
Movendo Technology Srl, of Genoa, Italy, has partnered with the Kessler Foundation, of West Orange, N.J., to explore potential applications for Movendo’s robotic platform, Hunova, to improve recovery after brain injury and stroke.
Tokyo-based Nihon Kohden Corp. reported the launch of its NK-Healthprotect Pop-up ICU Solution, an all-inclusive 16-bed system for the intensive care unit designed to allow hospitals to rapidly expand capacity during a health crisis such as COVID-19.
Palisade Co. LLC, of Ithaca, N.Y., said a Louisiana Department of Health and Hospitals official reported the company’s @Risk decision support software estimated a 90% probability range of 27,00 to 3,800 COVID-19 fatalities, in line with what the agency was experiencing.
Polyganics BV, of Groningen, Netherlands, reported the first patients treated in its first-in-human study for Actiseal, its liver and pancreas sealant patch. The prospective, multicenter SHIELDS trial is evaluating the safety and performance of Actiseal in reducing fluid leakage following elective hepato-pancreato-biliary surgery. A total of 80 adults will be enrolled and treated across seven European medical centers.
Sherlock Biosciences Inc., of Cambridge, Mass., reported the formation of the 221b Foundation, a nonprofit organization committed to addressing the COVID-19 pandemic by enabling access to intellectual property associated with the company’s Sherlock CRISPR-based technology. Proceeds from any company or third-party sales of Sherlock CRISPR COVID-19 products will support racial and gender diversity in science, technology, engineering, and math.
Ursa Health LLC, a Nashville, Tenn.-based provider of data analytics software to the health care industry, said that the Ursa Health Platform hosted by Microsoft Azure (also known as Ursa Studio) has earned certified status for information security by Hitrust.
Visage Imaging Inc., of San Diego, reported the signing of an agreement with NYU Langone Health to replace all legacy picture archiving and communication systems with the Visage 7 Enterprise imaging platform, implemented across four hospitals. The first sites will be scheduled to go live in in the first quarter of 2021. Visage also entered a multiyear research collaboration agreement with NYU Langone to design and develop next-generation products for enterprise imaging. NYU Langone will also become a member of the Visage AI Accelerator program.
Columbia, Md.-based digital health company Welldoc Inc. and the University of Maryland’s Center for Health Information and Decision System (CHIDS) reported findings as a result of their continued health data analytics partnership. CHIDS applied its machine learning and artificial intelligence (AI)-driven analytical methods to discover habits in how individuals with cardiometabolic diseases are using Welldoc’s tool, Bluestar. Preliminary data has already uncovered patterns of a user’s early engagement and habit formation that may predict higher persistence with the app. These initial data findings also show improvements in blood glucose levels months later for users who engaged early and often.